These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25191267)

  • 1. Huperzine A: Is it an Effective Disease-Modifying Drug for Alzheimer's Disease?
    Qian ZM; Ke Y
    Front Aging Neurosci; 2014; 6():216. PubMed ID: 25191267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia.
    Zhang HY; Zheng CY; Yan H; Wang ZF; Tang LL; Gao X; Tang XC
    Chem Biol Interact; 2008 Sep; 175(1-3):396-402. PubMed ID: 18565502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro production of huperzine A, a promising drug candidate for Alzheimer's disease.
    Ma X; Gang DR
    Phytochemistry; 2008 Jul; 69(10):2022-8. PubMed ID: 18538805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalent ligands derived from Huperzine A as acetylcholinesterase inhibitors.
    Haviv H; Wong DM; Silman I; Sussman JL
    Curr Top Med Chem; 2007; 7(4):375-87. PubMed ID: 17305579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylcholinesterase-independent protective effects of huperzine A against iron overload-induced oxidative damage and aberrant iron metabolism signaling in rat cortical neurons.
    Tao LX; Huang XT; Chen YT; Tang XC; Zhang HY
    Acta Pharmacol Sin; 2016 Nov; 37(11):1391-1400. PubMed ID: 27498774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing iron in the brain: a novel pharmacologic mechanism of huperzine A in the treatment of Alzheimer's disease.
    Huang XT; Qian ZM; He X; Gong Q; Wu KC; Jiang LR; Lu LN; Zhu ZJ; Zhang HY; Yung WH; Ke Y
    Neurobiol Aging; 2014 May; 35(5):1045-54. PubMed ID: 24332448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine.
    Wang R; Yan H; Tang XC
    Acta Pharmacol Sin; 2006 Jan; 27(1):1-26. PubMed ID: 16364207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer's Disease.
    Friedli MJ; Inestrosa NC
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease.
    Wang R; Tang XC
    Neurosignals; 2005; 14(1-2):71-82. PubMed ID: 15956816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of huperzine A and other Lycopodium alkaloids in Huperzia species grown under controlled conditions and in vitro.
    Ishiuchi K; Park JJ; Long RM; Gang DR
    Phytochemistry; 2013 Jul; 91():208-19. PubMed ID: 23306162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production and enhancement of the acetylcholinesterase inhibitor, huperzine A, from an endophytic Alternaria brassicae AGF041.
    Zaki AG; El-Shatoury EH; Ahmed AS; Al-Hagar OEA
    Appl Microbiol Biotechnol; 2019 Jul; 103(14):5867-5878. PubMed ID: 31119352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Huperzine A from Huperzia species--an ethnopharmacolgical review.
    Ma X; Tan C; Zhu D; Gang DR; Xiao P
    J Ethnopharmacol; 2007 Aug; 113(1):15-34. PubMed ID: 17644292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic Insight into the Binding of Huperzine a with Human Transferrin: Computational, Spectroscopic and Calorimetric Approaches.
    Atiya A; Alhumaydhi FA; Shamsi A; Olatunde A; Alsagaby SA; Al Abdulmonem W; Sharaf SE; Shahwan M
    ACS Omega; 2022 Nov; 7(43):38361-38370. PubMed ID: 36340147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease.
    Zangara A
    Pharmacol Biochem Behav; 2003 Jun; 75(3):675-86. PubMed ID: 12895686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Huperzine A lowers intraocular pressure via the M3 mAChR and provides retinal neuroprotection via the M1 mAChR: a promising agent for the treatment of glaucoma.
    Yu P; Dong WP; Tang YB; Chen HZ; Cui YY; Bian XL
    Ann Transl Med; 2021 Feb; 9(4):332. PubMed ID: 33708959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation.
    Xiao XQ; Zhang HY; Tang XC
    J Neurosci Res; 2002 Jan; 67(1):30-6. PubMed ID: 11754078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huperzine A--an interesting anticholinesterase compound from the Chinese herbal medicine.
    Patocka J
    Acta Medica (Hradec Kralove); 1998; 41(4):155-7. PubMed ID: 9951045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research.
    Damar U; Gersner R; Johnstone JT; Schachter S; Rotenberg A
    Expert Rev Neurother; 2016 Jun; 16(6):671-80. PubMed ID: 27086593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel huperzine A based NMDA antagonists: insights from molecular docking, ADME/T and molecular dynamics simulation studies.
    Sigalapalli DK; Rangaswamy R; Tangellamudi ND
    RSC Adv; 2020 Jul; 10(43):25446-25455. PubMed ID: 35518623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Japanese Huperzia serrata extract and the constituent, huperzine A, ameliorate the scopolamine-induced cognitive impairment in mice.
    Ohba T; Yoshino Y; Ishisaka M; Abe N; Tsuruma K; Shimazawa M; Oyama M; Tabira T; Hara H
    Biosci Biotechnol Biochem; 2015; 79(11):1838-44. PubMed ID: 26059088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.